Article Details

Seagen (SGEN) Enters Exclusive Worldwide Licensing Agreement with RemGen to Develop ...

Retrieved on: 2021-08-09 14:59:11

Tags for this article:

Click the tags to see associated articles and topics

Seagen (SGEN) Enters Exclusive Worldwide Licensing Agreement with RemGen to Develop .... View article details on hiswai:

Excerpt

Seagen's therapies are based on antibody-drug conjugate technology that utilizes the targeting ability of monoclonal antibodies to deliver cell-killing ...

Article found on: www.investorsobserver.com

View Original Article

This article is found inside other hiswai user's workspaces. To start your own collection, sign up for free.

Sign Up